The crucial roles of m6A RNA modifications in cutaneous cancers: Implications in pathogenesis, metastasis, drug resistance, and targeted therapies

[1]  K. Kumari,et al.  Regulatory roles of RNA modifications in breast cancer , 2021, NAR cancer.

[2]  Yue Qiu,et al.  Characterization of m6A-Related Genes Landscape in Skin Cutaneous Melanoma to Aid Immunotherapy and Assess Prognosis , 2021, International journal of general medicine.

[3]  Yu-Ying He,et al.  METTL14 facilitates global genome repair and suppresses skin tumorigenesis , 2021, Proceedings of the National Academy of Sciences.

[4]  Shu Guo,et al.  Identification of the m6A RNA Methylation Regulators WTAP as a Novel Prognostic Biomarker and Genomic Alterations in Cutaneous Melanoma , 2021, Frontiers in Molecular Biosciences.

[5]  Hao Wu,et al.  METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/β-catenin pathway , 2021, Annals of translational medicine.

[6]  B. Ni,et al.  Physio-pathological effects of m6A modification and its potential contribution to melanoma , 2021, Clinical and Translational Oncology.

[7]  Fengqin Wang,et al.  The N6-methyladenosine RNA-binding protein YTHDF1 modulates the translation of TRAF6 to mediate the intestinal immune response , 2021, Nucleic acids research.

[8]  P. Ascierto,et al.  Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. , 2021, The Lancet. Oncology.

[9]  Ping Wang,et al.  m6A-Related lncRNAs Are Potential Biomarkers for the Prognosis of Metastatic Skin Cutaneous Melanoma , 2021, Frontiers in Molecular Biosciences.

[10]  Andrew J. Bannister,et al.  Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia , 2021, Nature.

[11]  Chuan He,et al.  Autophagy of the m6A mRNA demethylase FTO is impaired by low-level arsenic exposure to promote tumorigenesis , 2021, Nature Communications.

[12]  Ping Wu,et al.  N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway , 2021, Cell Death & Disease.

[13]  Pengyuan Yang,et al.  RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming , 2021, Nature Communications.

[14]  R. Dash,et al.  The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy , 2021, Frontiers in Oncology.

[15]  Huayang Wang,et al.  Identification and Verification of Molecular Subtypes with Enhanced Immune Infiltration Based on m6A Regulators in Cutaneous Melanoma , 2021, BioMed research international.

[16]  X. Dai,et al.  Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway , 2021, Oncogenesis.

[17]  P. Meng,et al.  METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner , 2021, Experimental & Molecular Medicine.

[18]  W. Han,et al.  YTHDF1-enhanced iron metabolism depends on TFRC m6A methylation , 2020, Theranostics.

[19]  Chuan He,et al.  Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer , 2020, Molecular Cancer.

[20]  J. Brooks,et al.  The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor , 2020, Proceedings of the National Academy of Sciences.

[21]  Jianjun Chen,et al.  YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7 , 2020, Cancer Research.

[22]  T. Rana,et al.  ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment , 2020, Proceedings of the National Academy of Sciences.

[23]  S. Morrison,et al.  Lymph protects metastasizing melanoma cells from ferroptosis , 2020, Nature.

[24]  Yuehua Wu,et al.  METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  M. Gu,et al.  Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis , 2020, Cancer Cell International.

[26]  Hui-Lung Sun,et al.  Control of Early B Cell Development by the RNA N6-Methyladenosine Methylation. , 2020, Cell reports.

[27]  S. Ju,et al.  The potential role of RNA N6-methyladenosine in Cancer progression , 2020, Molecular Cancer.

[28]  Guohui Wan,et al.  RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3‐mediated autophagy , 2020, The EMBO journal.

[29]  Huijun Sun,et al.  Organic anion transporters and PI3K–AKT–mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein , 2020, Journal of cellular physiology.

[30]  M. Yi,et al.  LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma , 2020, Molecular oncology.

[31]  Shiqing Ma,et al.  METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification , 2020, Molecular therapy. Nucleic acids.

[32]  Fang Wang,et al.  The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation , 2020, Nucleic acids research.

[33]  Yabing Chen,et al.  m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells , 2020, Autophagy.

[34]  P. Brousset,et al.  Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1 , 2020, Nature Communications.

[35]  G. Robertson,et al.  The role of exosomes in metastasis and progression of melanoma. , 2020, Cancer treatment reviews.

[36]  Nimit L. Patel,et al.  Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis , 2020, Nature Communications.

[37]  J. Utikal,et al.  Oncogenic Role of an Epigenetic Reader of m6A RNA Modification: YTHDF1 in Merkel Cell Carcinoma , 2020, Cancers.

[38]  M. Rodríguez-Paredes,et al.  DNA Methylation in Epidermal Differentiation, Aging, and Cancer. , 2020, The Journal of investigative dermatology.

[39]  D. Lambrechts,et al.  A variant in FTO gene shows association with histological ulceration in cutaneous melanoma , 2020, Journal of cutaneous pathology.

[40]  A. Eggermont,et al.  An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells , 2019, Nature Communications.

[41]  Q. Shu,et al.  Dynamic effects of Fto in regulating the proliferation and differentiation of adult neural stem cells of mice. , 2019, Human molecular genetics.

[42]  Shu-Bing Qian,et al.  m6A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2 , 2019, Nature Communications.

[43]  H. Ji,et al.  YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression , 2019, Nature Communications.

[44]  Q. Cao,et al.  N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma. , 2019, Cancer research.

[45]  E. Gagari,et al.  Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? , 2019, Current opinion in oncology.

[46]  Ok Hyun Park,et al.  Endoribonucleolytic Cleavage of m6A-Containing RNAs by RNase P/MRP Complex. , 2019, Molecular cell.

[47]  C. Deng,et al.  SMAD signaling promotes melanoma metastasis independently of phenotype switching. , 2019, The Journal of clinical investigation.

[48]  Hualiang Jiang,et al.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. , 2019, Cancer cell.

[49]  Guohui Wan,et al.  RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3 , 2019, Molecular Cancer.

[50]  M. Karelson,et al.  Discovery of Small Molecules that Activate RNA Methylation through Cooperative Binding to the METTL3-14-WTAP Complex Active Site. , 2019, Cell reports.

[51]  Xuetao Cao,et al.  CCR7 Chemokine Receptor‐Inducible lnc‐Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF‐1&agr;‐Mediated Glycolysis , 2019, Immunity.

[52]  Le Kang,et al.  RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. , 2019, Melanoma research.

[53]  Lehe Yang,et al.  Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway , 2019, Cancer management and research.

[54]  Yu Liang,et al.  The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network , 2019, Oncogene.

[55]  Cigall Kadoch,et al.  Chromatin regulatory mechanisms and therapeutic opportunities in cancer , 2019, Nature Cell Biology.

[56]  D. Hanahan,et al.  Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. , 2018, Cell reports.

[57]  Carola Berking,et al.  Melanoma , 2018, The Lancet.

[58]  Yu Zhang,et al.  m6A facilitates hippocampus-dependent learning and memory through Ythdf1 , 2018, Nature.

[59]  Chuan He,et al.  m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer , 2018, Nature Cell Biology.

[60]  B. Gregory,et al.  Nuclear m6A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development , 2018, PLoS genetics.

[61]  H. Zhe,et al.  FTO regulates the chemo‐radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β‐catenin through mRNA demethylation , 2018, Molecular carcinogenesis.

[62]  Yang Shi,et al.  Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal. , 2018, Molecular cell.

[63]  Chuan He,et al.  VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation , 2018, Cell Discovery.

[64]  C. Schmults,et al.  Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. , 2018, Journal of the American Academy of Dermatology.

[65]  E. Shin,et al.  YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma , 2018, Cancer Immunology Research.

[66]  Manolis Kellis,et al.  N6-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications , 2018, Nature Neuroscience.

[67]  James E. Bradner,et al.  R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling , 2018, Cell.

[68]  Howard Y. Chang,et al.  m6A mRNA methylation sustains Treg suppressive functions , 2018, Cell Research.

[69]  Yue Sheng,et al.  METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. , 2017, Cell stem cell.

[70]  Andrew J. Bannister,et al.  Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control , 2017, Nature.

[71]  Qi Zhou,et al.  Endothelial-specific m6A modulates mouse hematopoietic stem and progenitor cell development via Notch signaling , 2017, Cell Research.

[72]  Stefan Canzar,et al.  Temporal Control of Mammalian Cortical Neurogenesis by m6A Methylation , 2017, Cell.

[73]  C. Lenz,et al.  Human METTL16 is a N6‐methyladenosine (m6A) methyltransferase that targets pre‐mRNAs and various non‐coding RNAs , 2017, EMBO reports.

[74]  Rong Yin,et al.  Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers. , 2017, Cancer letters.

[75]  C. Horak,et al.  Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Chuan He,et al.  YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs , 2017, eLife.

[77]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[78]  Chuan He,et al.  Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis , 2017, Cell Research.

[79]  Tianlei Xu,et al.  Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. , 2017, Human molecular genetics.

[80]  Samie R Jaffrey,et al.  Molecular basis for the specific and multivariant recognitions of RNA substrates by human hnRNP A2/B1 , 2017, Nature Communications.

[81]  H. Rizos,et al.  Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma , 2017, Cancer.

[82]  Yang Xie,et al.  The U6 snRNA m6A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention , 2017, Cell.

[83]  Chuan He,et al.  YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA , 2017, Cell Research.

[84]  Chuan He,et al.  FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. , 2017, Cancer cell.

[85]  Chuan He,et al.  Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. , 2016, Trends in genetics : TIG.

[86]  Qiang Wang,et al.  Structural basis of N6-adenosine methylation by the METTL3–METTL14 complex , 2016, Nature.

[87]  James E Audia,et al.  Histone Modifications and Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[88]  Chuanzhao Zhang,et al.  Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA , 2016, Proceedings of the National Academy of Sciences.

[89]  Chuan He,et al.  N 6 -methyladenosine Modulates Messenger RNA Translation Efficiency , 2015, Cell.

[90]  P. Queirolo,et al.  Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. , 2015, Cancer treatment reviews.

[91]  M. Karagas,et al.  Drinking Water Arsenic Contamination, Skin Lesions, and Malignancies: A Systematic Review of the Global Evidence , 2015, Current Environmental Health Reports.

[92]  Erez Y. Levanon,et al.  m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation , 2015, Science.

[93]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[94]  Cheng Luo,et al.  Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5 , 2014, Nucleic acids research.

[95]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[96]  G. Pupo,et al.  BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.

[97]  Samir Adhikari,et al.  Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase , 2014, Cell Research.

[98]  Makoto Naito,et al.  Identification of Wilms' Tumor 1-associating Protein Complex and Its Role in Alternative Splicing and the Cell Cycle* , 2013, The Journal of Biological Chemistry.

[99]  Marko Hočevar,et al.  A variant in FTO shows association with melanoma risk not due to BMI , 2013, Nature Genetics.

[100]  Zhike Lu,et al.  ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. , 2013, Molecular cell.

[101]  E. Dennett,et al.  The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors , 2012, Journal of surgical oncology.

[102]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[103]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[104]  W. Lam,et al.  Arsenic Exposure and the Induction of Human Cancers , 2011, Journal of toxicology.

[105]  A. Castiñeiras,et al.  Synthesis, crystal structures and spectroscopy of meclofenamic acid and its metal complexes with manganese(II), copper(II), zinc(II) and cadmium(II). Antiproliferative and superoxide dismutase activity. , 2011, Journal of inorganic biochemistry.

[106]  Chengqi Yi,et al.  N6-Methyladenosine in Nuclear RNA is a Major Substrate of the Obesity-Associated FTO , 2011, Nature chemical biology.

[107]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[108]  E. Erdei,et al.  A new understanding in the epidemiology of melanoma , 2010, Expert review of anticancer therapy.

[109]  Roger D. Cox,et al.  Overexpression of Fto leads to increased food intake and results in obesity , 2010, Nature Genetics.

[110]  Myles G Cockburn,et al.  Increasing burden of melanoma in the United States. , 2009, The Journal of investigative dermatology.

[111]  U. Russo,et al.  Organotin meclofenamic complexes: Synthesis, crystal structures and antiproliferative activity of the first complexes of meclofenamic acid - novel anti-tuberculosis agents. , 2009, Journal of inorganic biochemistry.

[112]  B. Schönfisch,et al.  Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. , 2008, The Lancet. Oncology.

[113]  S. de Jong,et al.  Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1 , 2002, British Journal of Cancer.

[114]  G E Tomlinson,et al.  WTAP is a novel oncogenic protein in acute myeloid leukemia , 2014, Leukemia.

[115]  M. Jarvelin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S7 References a Common Variant in the Fto Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity , 2022 .